OncoSec Medical Inc (ONCSQ)

[chickpea598]

Oncosec's next generation go-anywhere electroporation device could add alot of expansion capability to Merck's pipeline of treatments if they wanted to attack non-responders to keytruda monotherapy in several different indications such as (TNBC, Head and Neck cancer, bladder cancer). After all, the market for all those patients that don't respond to Keytruda monotherapy represents a huge untapped market. If Oncosec is the only company to date that is specifically targeting the non-responders to Keytruda then they are ahead of the game assuming the upcoming results are great.

I was watching the Symposium videos posted on Oncosec's homepage yesterday and still feel reassured that these top scientists with all their optimism 2 1/2 years ago are still right about the great potential that Oncosec has to offer with the Immunopulse Platform.